The proposed merger of AbbVie Inc. and Allergan PLC aims answer AbbVie’s biggest worry: competition for Humira (adalimumab), the world’s top-selling drug with sales of nearly $20bn last year.
Humira biosimilars are expected to launch in the US in 2023. The US Food and Drug Administration has already approved...








